These results collectively suggested that treatment with exogenous TSG-6 exerted therapeutic effects on IBD mice by increasing intestinal tuft cells, which was mediated by interaction with Pou2f3. The gene discussed is TNFAIP6; the disease is inflammatory bowel disease.